Previous 10 | Next 10 |
The past month was rough for Amarin (AMRN) investors, to say the least. The company didn't receive a favorable ruling in their patent lawsuit against generics Dr. Reddy's (RDY) and Hikma (HKMPF ) in a U.S. District Court. Judge Miranda Du found that the generics infringed on Amarin's patents. ...
The breaking news Veteran biotech writer Adam Feuerstein, with Matthew Herper, reported for STAT after-hours Thursday on Gilead's ( GILD ) high-profile investigational antiviral, setting off bullish trading in GILD and in all major US stock market indices. The article's lede sets the basic...
Investing in biotech stocks can feel like a rollercoaster ride. Positive clinical trial results, drug approvals, or lucrative partnership announcements can send stocks soaring. These stocks can just as easily get eviscerated on drug failures, regulatory setbacks, and patent challenges. To rais...
Buying a stock when it's dipped in value can be a great way to secure a low price and strong return, assuming that it recovers. Amarin's (NASDAQ: AMRN) stock didn't just dip in March; it crashed more than 70%. When news broke on March 30 that a district judge in Nevada invalidated pate...
While we typically focus on penny stocks that are currently meeting the definition, we have started getting questions on research on other popular stocks. Not necessarily research in the sense of a full report but rather if a high-flying equity was ever a penny stock in the past. This is never...
Should you invest? Should you invest in biotech stocks? Should you invest in biotech stocks right now ? I think there are good answers to each part of the question and to the overall question itself. As you'll see, however, to get to those answers will require even more questions to be address...
Amarin ( AMRN ) held a conference call yesterday after announcing earnings - this was the first in-depth call after the ANDA lawsuit fiasco, and investors were eager to hear what the CEO had to say. CEO John Thero began the call with a note that they did $150mn in global revenue in Q1, h...
Amarin Corporation plc (AMRN) Q1 2020 Results Earnings Conference Call April 13, 2020, 04:30 PM ET Company Participants Elisabeth Schwartz - Senior Director of Investor Relations John Thero - President and Chief Executive Officer Conference Call Participants Presentation ...
Image source: The Motley Fool. Amarin Corporation plc (NASDAQ: AMRN) Q1 2020 Earnings Call Apr 13, 2020 , 4:30 p.m. ET Operator Continue reading
Preliminary Amarin (NASDAQ: AMRN ) Q1 numbers show revenue of about $150M vs. estimates for roughly $130M. More news on: Amarin Corporation plc, Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...